Physician

Dayanand Makey, MD

According to 2025 Medicare claims, Dayanand Makey, MD (NPI: 1760788368) practices nephrology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is KIDNEY & HYPERTENSION CONSULTANTS, INC. (NPI: 1770524696; TIN: 34-1421578) and primary practice location at 44708-6220. Makey is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Makey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 425 traditional Medicare patients, billed 4,723 HCPCS/CPT codes, and received $243,721 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,597 prescription claims across 358 beneficiaries totaling $168,554 in drug costs, led by Jardiance (Empagliflozin). 2020 DME data shows 11 claims. Open Payments data shows 8 records totaling $116. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have fallen sharply in recent years, from $52,422 to $168,554. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	522	9,964	$196,887
2016	604	10,561	$247,153
2017	646	4,803	$212,445
2018	618	5,654	$207,345
2019	630	5,872	$231,898
2020	579	4,069	$227,353
2021	574	3,768	$233,290
2022	458	2,753	$186,891
2023	461	6,930	$299,721
2024	425	4,723	$243,721

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	278	2,361	$52,422
2016	354	3,395	$166,923
2017	392	3,589	$221,397
2018	367	3,769	$627,392
2019	451	3,786	$1,098,025
2020	461	4,184	$1,059,267
2021	450	3,922	$454,027
2022	417	3,593	$219,947
2023	365	2,709	$136,276
2024	358	2,597	$168,554

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	34	$1,068
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$210
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	99	109	$120
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	152	366	$86
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	157	254	$60
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	74	127	$57
99454	Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days	52	509	$33

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	109	5,394	$102,744
Sevelamer Carbonate	Sevelamer Carbonate	67	2,370	$5,941
Nifedipine Er	Nifedipine	103	6,210	$3,608
Potassium Citrate Er	Potassium Citrate	15	1,174	$3,525
Eplerenone	Eplerenone	30	1,776	$2,745

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$116	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dayanand Makey, MD?

Tedicare shows public-source Medicare data for Dayanand Makey, MD (NPI 1760788368), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dayanand Makey, MD have ACO affiliation data?

Dayanand Makey, MD is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Dayanand Makey, MD?

Dayanand Makey, MD is linked to KIDNEY & HYPERTENSION CONSULTANTS, INC. (billing NPI 1770524696) in the available physician profile data.

Does Dayanand Makey, MD have Open Payments data?

Dayanand Makey, MD has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.